PL2324835T3 - Kompozycja zawierająca substancje hamujące krystalizację - Google Patents

Kompozycja zawierająca substancje hamujące krystalizację

Info

Publication number
PL2324835T3
PL2324835T3 PL09784119T PL09784119T PL2324835T3 PL 2324835 T3 PL2324835 T3 PL 2324835T3 PL 09784119 T PL09784119 T PL 09784119T PL 09784119 T PL09784119 T PL 09784119T PL 2324835 T3 PL2324835 T3 PL 2324835T3
Authority
PL
Poland
Prior art keywords
composition
dialysis liquid
inhibitor substances
crystallisation inhibitor
crystallisation
Prior art date
Application number
PL09784119T
Other languages
English (en)
Inventor
Freixedas Félix Grases
Bestard Joan Perello
Espinosa Fernando Tur
Bauza Antonia Costa
Almirall Rafael M. Prieto
Muñiz Isabel Gomila
Original Assignee
Universitat De Les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Les Illes Balears filed Critical Universitat De Les Illes Balears
Publication of PL2324835T3 publication Critical patent/PL2324835T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
PL09784119T 2008-08-06 2009-05-14 Kompozycja zawierająca substancje hamujące krystalizację PL2324835T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200802363A ES2332636B1 (es) 2008-08-06 2008-08-06 Composicion de liquido de dialisis.

Publications (1)

Publication Number Publication Date
PL2324835T3 true PL2324835T3 (pl) 2017-01-31

Family

ID=41058532

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16172654T PL3103456T3 (pl) 2008-08-06 2009-05-14 Kompozycja płynu dializacyjnego zawierająca substancje hamujące krystalizację
PL09784119T PL2324835T3 (pl) 2008-08-06 2009-05-14 Kompozycja zawierająca substancje hamujące krystalizację

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16172654T PL3103456T3 (pl) 2008-08-06 2009-05-14 Kompozycja płynu dializacyjnego zawierająca substancje hamujące krystalizację

Country Status (19)

Country Link
US (4) US8778912B2 (pl)
EP (2) EP3103456B1 (pl)
JP (4) JP2011529759A (pl)
CN (2) CN104224809A (pl)
AU (1) AU2009281096B2 (pl)
CA (2) CA2732881C (pl)
CY (2) CY1118089T1 (pl)
DK (2) DK3103456T3 (pl)
ES (3) ES2332636B1 (pl)
HK (1) HK1203843A1 (pl)
HR (2) HRP20161170T1 (pl)
HU (2) HUE049269T2 (pl)
LT (2) LT2324835T (pl)
MX (1) MX2011001278A (pl)
PL (2) PL3103456T3 (pl)
PT (2) PT3103456T (pl)
RU (2) RU2535094C2 (pl)
SI (2) SI2324835T1 (pl)
WO (1) WO2010018278A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
DE102014013885A1 (de) 2014-09-18 2016-03-24 Fresenius Medical Care Deutschland Gmbh Dialyselösung
US10758565B2 (en) * 2015-06-04 2020-09-01 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
DE102015007842A1 (de) * 2015-06-18 2016-12-22 Fresenius Medical Care Deutschland Gmbh Dialyselösung
EA037572B1 (ru) * 2015-12-11 2021-04-15 Этх Цюрих Производные инозитола для применения в патологической кристаллизации
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
CN107550992B (zh) * 2017-08-16 2018-05-25 安徽天康(集团)股份有限公司 一种治疗痛风的药物及其制备方法
AU2018445164B2 (en) * 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
CN113365636A (zh) 2019-01-30 2021-09-07 萨尼菲特治疗有限公司 用于增加组织灌注的磷酸肌醇化合物
CN113811308A (zh) * 2019-05-10 2021-12-17 费森尤斯医疗护理德国有限责任公司 用于制备透析溶液的组合物和浓缩物、相应的透析溶液和包含容器的组合
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
CA3263498A1 (en) 2022-07-29 2024-02-01 Vifor (International) Ltd. IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS INTENDED FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION AND PREVENTION OF ECTOPIC CALCIFICATION
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
EP0637237B1 (en) * 1993-02-23 2004-05-19 Brigham And Women's Hospital, Inc. Calcium receptor-active molecules
JPH1149671A (ja) * 1997-08-06 1999-02-23 Baxter Internatl Inc 腹膜透析液
RU2126973C1 (ru) * 1997-10-07 1999-02-27 Слюсарь Николай Николаевич Способ коррекции нарушений фосфоинозитидного обмена
EG24303A (en) * 1998-10-20 2009-01-12 Advanced Renal Technologies Buffered compositions for dialysis
DE19912850B4 (de) * 1999-03-22 2005-04-07 Fresenius Medical Care Deutschland Gmbh Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung
DE29910454U1 (de) * 1999-06-10 1999-09-23 Vitasyn GmbH, 10789 Berlin Mittel zur Therapie von Hyperphosphatämie
ATE311203T1 (de) * 1999-10-15 2005-12-15 Dow Global Technologies Inc Dialyselösung die polyglycol als osmotischen mittels enthält
JP2002249433A (ja) * 2000-12-19 2002-09-06 Sumitomo Pharmaceut Co Ltd 血管石灰化抑制剤
JP2003238414A (ja) * 2001-12-13 2003-08-27 Sangaku Renkei Kiko Kyushu:Kk 医薬組成物
CN101094681A (zh) * 2003-10-28 2007-12-26 爱默蕾大学 透析液及其相关方法和系统
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
ES2288126B2 (es) * 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.

Also Published As

Publication number Publication date
BRPI0911938A2 (pt) 2015-10-20
JP6412068B2 (ja) 2018-10-24
WO2010018278A2 (es) 2010-02-18
HUE049269T2 (hu) 2020-09-28
CY1122973T1 (el) 2021-10-29
EP2324835B1 (en) 2016-07-20
MX2011001278A (es) 2011-05-30
PT3103456T (pt) 2020-05-06
US20150374752A1 (en) 2015-12-31
JP2019019134A (ja) 2019-02-07
JP5978251B2 (ja) 2016-08-24
US20170119799A1 (en) 2017-05-04
AU2009281096A1 (en) 2010-02-18
CA2975801C (en) 2018-08-07
ES2785566T3 (es) 2020-10-07
US20140302166A1 (en) 2014-10-09
WO2010018278A3 (es) 2010-12-16
HUE031173T2 (en) 2017-07-28
HK1203843A1 (en) 2015-11-06
CN104224809A (zh) 2014-12-24
LT3103456T (lt) 2020-05-11
CY1118089T1 (el) 2017-06-28
PT2324835T (pt) 2016-10-25
EP3103456A1 (en) 2016-12-14
HRP20161170T1 (hr) 2016-11-04
RU2014127746A (ru) 2016-01-27
EP2324835A2 (en) 2011-05-25
JP2016183196A (ja) 2016-10-20
CN102143754A (zh) 2011-08-03
HRP20200733T1 (hr) 2020-10-16
JP2011529759A (ja) 2011-12-15
SI3103456T1 (sl) 2020-09-30
US9155750B2 (en) 2015-10-13
PL3103456T3 (pl) 2020-09-21
EP3103456B1 (en) 2020-02-12
LT2324835T (lt) 2016-10-10
US8778912B2 (en) 2014-07-15
ES2332636A1 (es) 2010-02-09
RU2691060C2 (ru) 2019-06-10
US20110172194A1 (en) 2011-07-14
ES2595227T3 (es) 2016-12-28
ES2332636B1 (es) 2011-02-10
SI2324835T1 (sl) 2017-01-31
CA2732881C (en) 2017-09-26
AU2009281096B2 (en) 2016-07-21
JP2014210782A (ja) 2014-11-13
RU2011115356A (ru) 2012-10-27
DK3103456T3 (da) 2020-05-04
RU2535094C2 (ru) 2014-12-10
JP6799041B2 (ja) 2020-12-09
DK2324835T3 (en) 2016-11-14
CA2732881A1 (en) 2010-02-18
CA2975801A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
PT3103456T (pt) Composição do líquido de diálise compreendendo substâncias inibidoras de cristalização
ZA201008806B (en) Liquid crystal compositions comprising mesogen containing compounds
PL3110901T3 (pl) Zastosowanie r-1233 w cieczowych urządzeniach chłodzących
EP2399942A4 (en) POLYMERIZABLE LIQUID CRYSTAL COMPOSITION
GB0804572D0 (en) Preparation of desulphurisation materials
BRPI0910515A2 (pt) composição líquida
PL2096090T3 (pl) Zastosowanie reaktywnego ciekłego spoiwa ceramicznego
PL1975226T3 (pl) Płynna kompozycja do obróbki
PL2271660T3 (pl) Stabilizowane ciekłe kompozycje enzymów
PL3329912T3 (pl) Ciekła kompozycja
GB0807474D0 (en) Determination of Composition of Liquids
PL2313052T3 (pl) Ciekła kompozycja myjąca do ciała
PL2305275T3 (pl) Ciekła kompozycja zawierająca koordynacyjny związek cisplatyny
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
PT2291654T (pt) Preparação e composição de proteínas inibidoras de interalfa do sangue
IL208403A0 (en) Compositions and use of epas1 inhibitors
IL209073A0 (en) Liquid cleaning compositions and manufacture
ZA201100250B (en) Composition of middle distillate
EP2036900A4 (en) SMEKTICAL LIQUID CRYSTAL CONNECTION
GB0813840D0 (en) Improved liquid crystal compounds
SI2076243T1 (sl) Tekoäśa formulacija g-csf-ja
GB0910075D0 (en) Dielctic Characterisation of liquid crystals
EP2300354A4 (en) DISTRIBUTION OF FLUIDS
IL211688A (en) Crystalline form ii of calcium 3-acetylaminopropane-1-sulfonate
GB0803417D0 (en) Preparation of liquid concentrate milk-substitute